Glucotrack to present first-in-human CBGM trial data at ATTD 2025 conference in Amsterdam

Glucotrack, Inc.

Safety and performance data from first-in-human trial of implantable CBGM system to be presented at ATTD conference, March 19-22, 2025.
Device measures glucose directly from blood, not interstitial fluid, with no on-body wearables, designed for 3-year continuous monitoring.
Trial is an early feasibility study in adults with diabetes; results support advancement to chronic implant study.
CEO Paul Goode highlights potentially transformative advancement in diabetes management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.